1Cell.Ai shared a post on LinkedIn:
“Liquid Biopsy Evolution: Multi-Omic and Beyond ctDNA
Liquid biopsy will be everywhere at AACR 2026. From Illumina’s symposium on DNA methylation and spatial transcriptomics to Labcorp’s panels on the biomarker continuum, the industry is racing toward “Next-Gen” liquid biopsies.
The trend is clear: Liquid biopsy is moving beyond simple ctDNA analysis into complex, multi-modal platforms that use both circulating tumor cells and ctDNA combined for tumor profiling.
The 1Cell.Ai Perspective: Whole Cell + Fragment is the future
Most current discussions are limited to ctDNA which are small fragments of the tumor and are shed from dying cells. No matter how sensitive the ctDNA technology is, it is bound to miss important information about the tumor DNA level alterations. Moreover, ctDNA is limited to DNA. While some emerging liquid biopsies are demonstrating their ability to provide a partial picture of RNA through methylation and histone marks, the protein picture is largely out of bounds for current liquid biopsies. This indeed is a big cap today and is particularly severe given the growth of protein directed therapies such as ADCs and Bispecifics.
This is where 1Cell.Ai changes the game. While the industry settles for “bulk” averages, we provide Cell-Level Resolution + ctDNA:
- True Multi-Omics: We analyze 15-20 proteins on single cells directly from blood.
- Deep Genomic Coverage: Our 1080-gene panel runs across both CTCs and ctDNA simultaneously.
- Future-Ready RNA: We are actively extending our single-cell method to include full RNASeq capabilities.
As Dr. Razelle Kurzrock highlights in the clip, aggressive killers like pancreatic cancer evolve too fast for a “partial picture.” If you want to see the first liquid biopsy platform that captures the full trifecta – DNA, RNA, and Protein by analyzing both CTC+ctDNA, let’s connect at AACR.”
Visit 1Cell.Ai to see the data․
Watch the Razelle Kurzrock clip
Other articles featuring Razelle Kurzrock on OncoDaily.